ID   ACS2B_HUMAN             Reviewed;         577 AA.
AC   Q68CK6; Q86YT1;
DT   02-OCT-2007, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   28-JUN-2023, entry version 141.
DE   RecName: Full=Acyl-coenzyme A synthetase ACSM2B, mitochondrial;
DE            EC=6.2.1.2 {ECO:0000269|PubMed:10434065};
DE   AltName: Full=Acyl-CoA synthetase medium-chain family member 2B;
DE   AltName: Full=Benzoate--CoA ligase;
DE            EC=6.2.1.25 {ECO:0000269|PubMed:10434065, ECO:0000269|PubMed:12616642};
DE   AltName: Full=Butyrate--CoA ligase 2B;
DE   AltName: Full=Butyryl-coenzyme A synthetase 2B;
DE   AltName: Full=Middle-chain acyl-CoA synthetase 2B;
DE   AltName: Full=Xenobiotic/medium-chain fatty acid-CoA ligase HXM-A {ECO:0000303|PubMed:10434065};
DE   Flags: Precursor;
GN   Name=ACSM2B; Synonyms=ACSM2; ORFNames=HYST1046;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 152-163 AND 483-491,
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND CATALYTIC ACTIVITY.
RC   TISSUE=Liver;
RX   PubMed=12616642; DOI=10.1002/jbt.10056;
RA   Vessey D.A., Lau E., Kelley M., Warren R.S.;
RT   "Isolation, sequencing, and expression of a cDNA for the HXM-A form of
RT   xenobiotic/medium-chain fatty acid:CoA ligase from human liver
RT   mitochondria.";
RL   J. Biochem. Mol. Toxicol. 17:1-6(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15221005; DOI=10.1038/sj.onc.1207782;
RA   Yamada S., Ohira M., Horie H., Ando K., Takayasu H., Suzuki Y., Sugano S.,
RA   Hirata T., Goto T., Matsunaga T., Hiyama E., Hayashi Y., Ando H., Suita S.,
RA   Kaneko M., Sasaki F., Hashizume K., Ohnuma N., Nakagawara A.;
RT   "Expression profiling and differential screening between hepatoblastomas
RT   and the corresponding normal livers: identification of high expression of
RT   the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas.";
RL   Oncogene 23:5901-5911(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   FUNCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, COFACTOR, TISSUE
RP   SPECIFICITY, ACTIVITY REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10434065; DOI=10.1016/s0304-4165(99)00088-4;
RA   Vessey D.A., Kelley M., Warren R.S.;
RT   "Characterization of the CoA ligases of human liver mitochondria catalyzing
RT   the activation of short- and medium-chain fatty acids and xenobiotic
RT   carboxylic acids.";
RL   Biochim. Biophys. Acta 1428:455-462(1999).
RN   [5]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19634011; DOI=10.1007/s10528-009-9273-z;
RA   Boomgaarden I., Vock C., Klapper M., Doering F.;
RT   "Comparative analyses of disease risk genes belonging to the acyl-CoA
RT   synthetase medium-chain (ACSM) family in human liver and cell lines.";
RL   Biochem. Genet. 47:739-748(2009).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-513, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [7]
RP   REVIEW.
RX   PubMed=27351777; DOI=10.1080/17425255.2016.1206888;
RA   van der Sluis R., Erasmus E.;
RT   "Xenobiotic/medium chain fatty acid: CoA ligase - a critical review on its
RT   role in fatty acid metabolism and the detoxification of benzoic acid and
RT   aspirin.";
RL   Expert Opin. Drug Metab. Toxicol. 12:1169-1179(2016).
CC   -!- FUNCTION: Catalyzes the activation of fatty acids by CoA to produce an
CC       acyl-CoA, the first step in fatty acid metabolism (PubMed:10434065,
CC       PubMed:12616642). Capable of activating medium-chain fatty acids (e.g.
CC       butyric (C4) to decanoic (C10) acids), and certain carboxylate-
CC       containing xenobiotics, e.g. benzoate (PubMed:10434065,
CC       PubMed:12616642). {ECO:0000269|PubMed:10434065,
CC       ECO:0000269|PubMed:12616642}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a medium chain fatty acid + ATP + CoA = a medium-chain fatty
CC         acyl-CoA + AMP + diphosphate; Xref=Rhea:RHEA:48340,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:59558, ChEBI:CHEBI:90546, ChEBI:CHEBI:456215; EC=6.2.1.2;
CC         Evidence={ECO:0000269|PubMed:10434065};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48341;
CC         Evidence={ECO:0000305|PubMed:10434065};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + benzoate + CoA = AMP + benzoyl-CoA + diphosphate;
CC         Xref=Rhea:RHEA:10132, ChEBI:CHEBI:16150, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57369,
CC         ChEBI:CHEBI:456215; EC=6.2.1.25;
CC         Evidence={ECO:0000269|PubMed:10434065, ECO:0000269|PubMed:12616642};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10133;
CC         Evidence={ECO:0000305|PubMed:10434065, ECO:0000305|PubMed:12616642};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + CoA + hexanoate = AMP + diphosphate + hexanoyl-CoA;
CC         Xref=Rhea:RHEA:43740, ChEBI:CHEBI:17120, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:62620,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000269|PubMed:10434065};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43741;
CC         Evidence={ECO:0000305|PubMed:10434065};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + butanoate + CoA = AMP + butanoyl-CoA + diphosphate;
CC         Xref=Rhea:RHEA:46172, ChEBI:CHEBI:17968, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57371,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000269|PubMed:10434065};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46173;
CC         Evidence={ECO:0000305|PubMed:10434065};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + CoA + octanoate = AMP + diphosphate + octanoyl-CoA;
CC         Xref=Rhea:RHEA:33631, ChEBI:CHEBI:25646, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57386,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000269|PubMed:10434065};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33632;
CC         Evidence={ECO:0000305|PubMed:10434065};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + CoA + decanoate = AMP + decanoyl-CoA + diphosphate;
CC         Xref=Rhea:RHEA:33627, ChEBI:CHEBI:27689, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:61430,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000269|PubMed:10434065};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33628;
CC         Evidence={ECO:0000305|PubMed:10434065};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10434065};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:10434065};
CC   -!- ACTIVITY REGULATION: Activated by monovalent cations, such as
CC       potassium, rubidium or ammonium. {ECO:0000269|PubMed:10434065}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=13 uM for benzoate {ECO:0000269|PubMed:10434065};
CC         KM=800 uM for butyrate {ECO:0000269|PubMed:10434065};
CC         KM=110 uM for decanoate {ECO:0000269|PubMed:10434065};
CC         KM=74 uM for hexanoate {ECO:0000269|PubMed:10434065};
CC         KM=60 uM for laurate {ECO:0000269|PubMed:10434065};
CC         KM=160 uM for phenylacetate {ECO:0000269|PubMed:10434065};
CC         KM=7.4 uM for salicylate {ECO:0000269|PubMed:10434065};
CC         Vmax=103 nmol/min/mg enzyme for benzoate
CC         {ECO:0000269|PubMed:10434065};
CC         Vmax=27 nmol/min/mg enzyme for butyrate
CC         {ECO:0000269|PubMed:10434065};
CC         Vmax=15 nmol/min/mg enzyme for decanoate
CC         {ECO:0000269|PubMed:10434065};
CC         Vmax=88 nmol/min/mg enzyme for hexanoate
CC         {ECO:0000269|PubMed:10434065};
CC         Vmax=0.2 nmol/min/mg enzyme for laurate
CC         {ECO:0000269|PubMed:10434065};
CC         Vmax=29 nmol/min/mg enzyme for phenylacetate
CC         {ECO:0000269|PubMed:10434065};
CC         Vmax=0.7 nmol/min/mg enzyme for salicylate
CC         {ECO:0000269|PubMed:10434065};
CC       pH dependence:
CC         Optimum pH is 8.8. {ECO:0000269|PubMed:10434065};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:12616642}.
CC   -!- INTERACTION:
CC       Q68CK6; P43364: MAGEA11; NbExp=3; IntAct=EBI-2880280, EBI-739552;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:10434065,
CC       ECO:0000269|PubMed:12616642, ECO:0000269|PubMed:19634011}.
CC   -!- TISSUE SPECIFICITY: Detected in liver. {ECO:0000269|PubMed:10434065,
CC       ECO:0000269|PubMed:19634011}.
CC   -!- SIMILARITY: Belongs to the ATP-dependent AMP-binding enzyme family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY160217; AAO17576.1; -; mRNA.
DR   EMBL; AB073604; BAD38642.1; -; mRNA.
DR   EMBL; AC141053; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC141273; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS10586.1; -.
DR   RefSeq; NP_001098539.1; NM_001105069.1.
DR   RefSeq; NP_872423.3; NM_182617.3.
DR   AlphaFoldDB; Q68CK6; -.
DR   SMR; Q68CK6; -.
DR   BioGRID; 131510; 5.
DR   IntAct; Q68CK6; 2.
DR   STRING; 9606.ENSP00000327453; -.
DR   SwissLipids; SLP:000001827; -.
DR   iPTMnet; Q68CK6; -.
DR   PhosphoSitePlus; Q68CK6; -.
DR   BioMuta; ACSM2B; -.
DR   DMDM; 296434397; -.
DR   EPD; Q68CK6; -.
DR   MassIVE; Q68CK6; -.
DR   MaxQB; Q68CK6; -.
DR   PaxDb; Q68CK6; -.
DR   PeptideAtlas; Q68CK6; -.
DR   ProteomicsDB; 66005; -.
DR   Antibodypedia; 55971; 5 antibodies from 4 providers.
DR   DNASU; 348158; -.
DR   Ensembl; ENST00000329697.10; ENSP00000327453.6; ENSG00000066813.14.
DR   Ensembl; ENST00000414188.6; ENSP00000390378.3; ENSG00000066813.14.
DR   Ensembl; ENST00000565232.5; ENSP00000454995.1; ENSG00000066813.14.
DR   Ensembl; ENST00000567001.5; ENSP00000456378.1; ENSG00000066813.14.
DR   GeneID; 348158; -.
DR   KEGG; hsa:348158; -.
DR   MANE-Select; ENST00000329697.10; ENSP00000327453.6; NM_001105069.2; NP_001098539.1.
DR   UCSC; uc002dhj.5; human.
DR   AGR; HGNC:30931; -.
DR   CTD; 348158; -.
DR   DisGeNET; 348158; -.
DR   GeneCards; ACSM2B; -.
DR   HGNC; HGNC:30931; ACSM2B.
DR   HPA; ENSG00000066813; Group enriched (kidney, liver).
DR   MIM; 614359; gene.
DR   neXtProt; NX_Q68CK6; -.
DR   OpenTargets; ENSG00000066813; -.
DR   PharmGKB; PA162375437; -.
DR   VEuPathDB; HostDB:ENSG00000066813; -.
DR   eggNOG; KOG1175; Eukaryota.
DR   GeneTree; ENSGT00940000164294; -.
DR   InParanoid; Q68CK6; -.
DR   OMA; RVAAYKY; -.
DR   OrthoDB; 5474118at2759; -.
DR   PhylomeDB; Q68CK6; -.
DR   TreeFam; TF354264; -.
DR   PathwayCommons; Q68CK6; -.
DR   Reactome; R-HSA-177128; Conjugation of salicylate with glycine.
DR   Reactome; R-HSA-177135; Conjugation of benzoate with glycine.
DR   Reactome; R-HSA-177162; Conjugation of phenylacetate with glutamine.
DR   Reactome; R-HSA-9749641; Aspirin ADME.
DR   SABIO-RK; Q68CK6; -.
DR   SignaLink; Q68CK6; -.
DR   BioGRID-ORCS; 348158; 14 hits in 1147 CRISPR screens.
DR   ChiTaRS; ACSM2B; human.
DR   GeneWiki; ACSM2B; -.
DR   GenomeRNAi; 348158; -.
DR   Pharos; Q68CK6; Tdark.
DR   PRO; PR:Q68CK6; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q68CK6; protein.
DR   Bgee; ENSG00000066813; Expressed in right lobe of liver and 103 other tissues.
DR   ExpressionAtlas; Q68CK6; baseline and differential.
DR   Genevisible; Q68CK6; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0018858; F:benzoate-CoA ligase activity; IDA:UniProtKB.
DR   GO; GO:0047760; F:butyrate-CoA ligase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016405; F:CoA-ligase activity; TAS:Reactome.
DR   GO; GO:0102391; F:decanoate-CoA ligase activity; IEA:RHEA.
DR   GO; GO:0015645; F:fatty acid ligase activity; IBA:GO_Central.
DR   GO; GO:0004321; F:fatty-acyl-CoA synthase activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006637; P:acyl-CoA metabolic process; IBA:GO_Central.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   Gene3D; 3.30.300.30; -; 1.
DR   Gene3D; 3.40.50.12780; N-terminal domain of ligase-like; 1.
DR   InterPro; IPR025110; AMP-bd_C.
DR   InterPro; IPR045851; AMP-bd_C_sf.
DR   InterPro; IPR020845; AMP-binding_CS.
DR   InterPro; IPR000873; AMP-dep_Synth/Lig_com.
DR   InterPro; IPR042099; ANL_N_sf.
DR   PANTHER; PTHR43605; ACYL-COENZYME A SYNTHETASE; 1.
DR   PANTHER; PTHR43605:SF3; ACYL-COENZYME A SYNTHETASE ACSM2B, MITOCHONDRIAL; 1.
DR   Pfam; PF00501; AMP-binding; 1.
DR   Pfam; PF13193; AMP-binding_C; 1.
DR   SUPFAM; SSF56801; Acetyl-CoA synthetase-like; 1.
DR   PROSITE; PS00455; AMP_BINDING; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Direct protein sequencing; Fatty acid metabolism; Ligase;
KW   Lipid metabolism; Magnesium; Metal-binding; Mitochondrion;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Transit peptide.
FT   TRANSIT         1..46
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000255"
FT   CHAIN           47..577
FT                   /note="Acyl-coenzyme A synthetase ACSM2B, mitochondrial"
FT                   /id="PRO_0000306094"
FT   BINDING         139
FT                   /ligand="CoA"
FT                   /ligand_id="ChEBI:CHEBI:57287"
FT                   /evidence="ECO:0000250"
FT   BINDING         221..229
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         359..364
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         364
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         446
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         461
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         469..471
FT                   /ligand="CoA"
FT                   /ligand_id="ChEBI:CHEBI:57287"
FT                   /evidence="ECO:0000250"
FT   BINDING         472
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         501
FT                   /ligand="CoA"
FT                   /ligand_id="ChEBI:CHEBI:57287"
FT                   /evidence="ECO:0000250"
FT   BINDING         532
FT                   /ligand="CoA"
FT                   /ligand_id="ChEBI:CHEBI:57287"
FT                   /evidence="ECO:0000250"
FT   BINDING         540..542
FT                   /ligand="CoA"
FT                   /ligand_id="ChEBI:CHEBI:57287"
FT                   /evidence="ECO:0000250"
FT   BINDING         557
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         513
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CONFLICT        46
FT                   /note="F -> L (in Ref. 1; AAO17576)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        96
FT                   /note="I -> V (in Ref. 1; AAO17576 and 2; BAD38642)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        133
FT                   /note="F -> I (in Ref. 1; AAO17576)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        136
FT                   /note="G -> E (in Ref. 1; AAO17576)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        143
FT                   /note="T -> A (in Ref. 1; AAO17576)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   577 AA;  64271 MW;  93A6F0581A47F222 CRC64;
     MHWLRKVQGL CTLWGTQMSS RTLYINSRQL VSLQWGHQEV PAKFNFASDV LDHWADMEKA
     GKRLPSPALW WVNGKGKELM WNFRELSENS QQAANILSGA CGLQRGDRVA VMLPRVPEWW
     LVILGCIRAG LIFMPGTIQM KSTDILYRLQ MSKAKAIVAG DEVIQEVDTV ASECPSLRIK
     LLVSEKSCDG WLNFKKLLNE ASTTHHCVET GSQEASAIYF TSGTSGLPKM AEHSYSSLGL
     KAKMDAGWTG LQASDIMWTI SDTGWILNIL GSLLESWTLG ACTFVHLLPK FDPLVILKTL
     SSYPIKSMMG APIVYRMLLQ QDLSSYKFPH LQNCLAGGES LLPETLENWR AQTGLDIREF
     YGQTETGLTC MVSKTMKIKP GYMGTAASCY DVQVIDDKGN VLPPGTEGDI GIRVKPIRPI
     GIFSGYVENP DKTAANIRGD FWLLGDRGIK DEDGYFQFMG RADDIINSSG YRIGPSEVEN
     ALMKHPAVVE TAVISSPDPV RGEVVKAFVI LASQFLSHDP EQLTKELQQH VKSVTAPYKY
     PRKIEFVLNL PKTVTGKIQR TKLRDKEWKM SGKARAQ
//
